Product Description: PD153035 (SU-5271; AG1517; ZM 252868) is a potent EGFR inhibitor with Ki and IC50 of 6 and 25 pM, respectively.
Applications: Cancer-Kinase/protease
Formula: C16H14BrN3O2
Citations: Biochim Biophys Acta Mol Basis Dis. 2023 Dec 13:166981./Cell Death Dis. 2022 Jul 25;13(7):647./Elife. 2015 Feb 10;4:e05178./Gen Comp Endocrinol. 2020 Dec 1;299:113616./Int J Stem Cells. 2022 Jun 30./J Toxicol Sci. 2023 Nov 14;48(12):655-663./Nat Commun. 2018 Jun 5;9(1):2174./bioRxiv. 2024 Apr 4.
References: [1]Bridges AJ, et al. Tyrosine kinase inhibitors. 8. An unusually steep structure-activity relationship for analogues of 4-(3-bromoanilino)-6,7-dimethoxyquinazoline (PD 153035), a potent inhibitor of the epidermal growth factor receptor. J Med Chem. 1996 Jan 5;39(1):267-76./[2]Fry DW, et al. A specific inhibitor of the epidermal growth factor receptor tyrosine kinase. Science. 1994 Aug 19;265(5175):1093-5./[3]Bos M, et al. PD153035, a tyrosine kinase inhibitor, prevents epidermal growth factor receptoractivation and inhibits growth of cancer cells in a receptor number-dependent manner. Clin Cancer Res. 1997 Nov;3(11):2099-106./[4]Kunkel MW, et al. Inhibition of the epidermal growth factor receptor tyrosine kinase by PD153035 in human A431 tumors in athymic nude mice. Invest New Drugs. 1996;13(4):295-302.
CAS Number: 153436-54-5
Molecular Weight: 360.21
Compound Purity: 98.83
Research Area: Cancer
Solubility: DMSO : 33.33 mg/mL (ultrasonic)
Target: EGFR
English
Deutsch
